September 29, 2025
Septerna
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
September 22, 2025
Trace Neuroscience
Fierce Biotech Names Trace Neuroscience a “Fierce 15” Biotech Company of 2025
September 19, 2025
Candid Therapeutics
Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree
September 18, 2025
Seaport Therapeutics
Seaport Therapeutics to Participate in Upcoming Investor Conferences
September 11, 2025
Seaport Therapeutics
Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo (SPT-320) in Healthy Volunteers
September 11, 2025
Maze Therapeutics
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
September 11, 2025
Maze Therapeutics
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
September 09, 2025
ARTBIO
ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001
September 09, 2025
insitro
insitro partners with Lilly to build first-in-kind machine learning models to advance small molecule drug discovery
September 08, 2025
Rapport Therapeutics
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizuresra
September 02, 2025
Maze Therapeutics
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
August 21, 2025
Septerna
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseasesse
August 12, 2025
Marea Therapeutics
Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly
August 12, 2025
Maze Therapeutics
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
August 11, 2025
Septerna
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
August 07, 2025
ARTBIO
ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role
August 07, 2025
Rapport Therapeutics
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
August 05, 2025
Flare Therapeutics
Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer
August 05, 2025
Tango Therapeutics
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
August 04, 2025
Marea Therapeutics
Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD
July 29, 2025
ARTBIO
ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure
July 17, 2025
MOMA Therapeutics
MOMA Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial for MOMA-341,a Highly Potent and Selective Werner Helicase Inhibitor
July 17, 2025
Seaport Therapeutics
Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
July 14, 2025
Marea Therapeutics
Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025
July 01, 2025
Marea Therapeutics
Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer
June 27, 2025
Tango Therapeutics
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
June 24, 2025
Marea Therapeutics
Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025
June 20, 2025
Candid Therapeutics
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
June 05, 2025
Casma Therapeutics
Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease
May 29, 2025
Septerna
Septerna to Present at Jefferies Global Healthcare Conference
May 28, 2025
Flare Therapeutics
Flare Therapeutics to Participate in Jefferies Global Healthcare Conference
May 27, 2025
Tango Therapeutics
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
May 21, 2025
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
May 20, 2025
Marea Therapeutics
Marea Therapeutics Appoints Charmi Turner as Senior Vice President, People & Culture
May 16, 2025
Marea Therapeutics
Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
May 16, 2025
ARTBIO
ARTBIO Expands Radiopharmaceutical R&D Capabilities with Move to Oslo Science Park
May 15, 2025
Septerna
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
May 14, 2025
Maze Therapeutics
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
May 14, 2025
Septerna
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
May 12, 2025
Tango Therapeutics
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
May 08, 2025
Synnovation Therapeutics
Synnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of Directors
May 07, 2025
Marea Therapeutics
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
May 01, 2025
Tango Therapeutics
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
April 28, 2025
Clasp Therapeutics
Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial with a First-in-Class T-Cell Engager Designed to Target Cancer Cells with Absolute Specificity
April 24, 2025
Seaport Therapeutics
Seaport Therapeutics Presents New Preclinical Data on SPT-320 (Glyph Agomelatine) at the Society of Biological Psychiatry (SOBP) Annual Meeting
April 17, 2025
MOMA Therapeutics
MOMA Therapeutics to Present Multiple Posters at the American Association for Cancer Research Annual Meeting 2025
April 08, 2025
Merida Biosciences
Merida Biosciences Launches with $121M to Create Therapeutics for Multiple Autoimmune and Allergic Diseases
April 01, 2025
MOMA Therapeutics
MOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Directors and Expands Management Team
March 31, 2025
Maze Therapeutics
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
March 27, 2025
Septerna
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results